Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 13 articles:
HTML format



Single Articles


    April 2022
  1. SUN Q, Ye Y, Gui A, Sun X, et al
    MORTALIN-Ca(2+) axis drives innate rituximab resistance in diffuse large B-cell lymphoma.
    Cancer Lett. 2022 Apr 18:215678. doi: 10.1016/j.canlet.2022.215678.
    PubMed     Abstract available


    January 2022
  2. XING Y, Guo W, Wu M, Xie J, et al
    An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
    Cancer Lett. 2022 Jan 3. pii: S0304-3835(21)00658.
    PubMed     Abstract available


    December 2021
  3. DANG W, Cao P, Yan Q, Yang L, et al
    IGFBP7-AS1 is a p53-responsive long noncoding RNA downregulated by Epstein-Barr virus that contributes to viral tumorigenesis.
    Cancer Lett. 2021;523:135-147.
    PubMed     Abstract available


    October 2021
  4. CHEN ZQ, Cao ZR, Wang Y, Zhang X, et al
    Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kalpha against B cell lymphoma.
    Cancer Lett. 2021;524:206-218.
    PubMed     Abstract available


  5. COX MC, Bocci G
    Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds.
    Cancer Lett. 2021;524:144-150.
    PubMed     Abstract available


    September 2021
  6. SUN Y, Gao Y, Chen J, Huang L, et al
    CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.
    Cancer Lett. 2021 Sep 2. pii: S0304-3835(21)00438.
    PubMed     Abstract available


    March 2021
  7. YOU H, Wei L, Kaminska B
    Emerging insights into origin and pathobiology of primary central nervous system lymphoma.
    Cancer Lett. 2021 Mar 22. pii: S0304-3835(21)00104.
    PubMed     Abstract available


    January 2021
  8. MA Y, Bauer V, Riedel T, Ahmetlic F, et al
    Interleukin-10 counteracts T-helper type 1 responses in B-cell lymphoma and is a target for tumor immunotherapy.
    Cancer Lett. 2021;503:110-116.
    PubMed     Abstract available


    December 2020
  9. CASAGRANDE N, Borghese C, Favero A, Vicenzetto C, et al
    Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma.
    Cancer Lett. 2020 Dec 13. pii: S0304-3835(20)30665.
    PubMed     Abstract available


  10. CHEN XR, Yuan HH, Guo JH, Zhang WY, et al
    A signal peptide derived from Hsp60 induces protective cytotoxic T lymphocyte immunity against lymphoid malignancies independently of TAP and classical MHC-I.
    Cancer Lett. 2020;494:47-57.
    PubMed     Abstract available


    October 2020
  11. LU F, Zhao Y, Pang Y, Ji M, et al
    NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
    Cancer Lett. 2020 Oct 19. pii: S0304-3835(20)30547.
    PubMed     Abstract available


    August 2020
  12. LI X, Wei Y, Wei X
    Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
    Cancer Lett. 2020 Aug 13. pii: S0304-3835(20)30385.
    PubMed     Abstract available


    January 2020
  13. CHEN R, Wang M, Liu Q, Wu J, et al
    Sequential treatment with aT19cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice.
    Cancer Lett. 2020;469:162-172.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: